Development of Oral, Potent, and Selective CK1α Degraders for AML Therapy.
Huang L, Chen L, Chen L, Peng B, Zhou L, Sun Y, Shi T, Lu J, Lin W, Liu Y, Cao L, Li L, Han Q, Chen X, Yang P, Zhang S, Wang Z, Yang J, Guo Z, Jiang B, Lu W.
Huang L, et al. Among authors: chen x.
JACS Au. 2024 Nov 8;4(11):4423-4434. doi: 10.1021/jacsau.4c00762. eCollection 2024 Nov 25.
JACS Au. 2024.
PMID: 39610741
Free PMC article.